Detalhe da pesquisa
1.
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
Blood
; 139(8): 1147-1159, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34428285
2.
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
Blood
; 139(3): 413-423, 2022 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34570876
3.
Diffuse large B-cell lymphoma.
Hematol Oncol
; 2023 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37435781
4.
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.
Am J Hematol
; 98(6): 900-912, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36965007
5.
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.
Haematologica
; 107(7): 1608-1618, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34320785
6.
Follicular Lymphoma: a Focus on Current and Emerging Therapies
Oncology (Williston Park)
; 36(2): 97-106, 2022 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35180337
7.
Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
Br J Haematol
; 195(2): 201-209, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34341990
8.
Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation.
Br J Haematol
; 195(5): 757-763, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34581433
9.
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
N Engl J Med
; 379(18): 1711-1721, 2018 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30380386
10.
PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.
Blood
; 133(21): 2279-2290, 2019 05 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30910787
11.
Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.
Blood
; 133(1): 81-93, 2019 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30446494
12.
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.
Blood
; 134(15): 1238-1246, 2019 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31331918
13.
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration.
Haematologica
; 106(11): 2845-2852, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054118
14.
DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose?
Clin Adv Hematol Oncol
; 19(11): 698-709, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34807015
15.
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.
Oncologist
; 25(6): e993-e997, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32275786
16.
Diagnostic utility of STAT6YE361 expression in classical Hodgkin lymphoma and related entities.
Mod Pathol
; 33(5): 834-845, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31822802
17.
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.
Blood
; 132(19): 2016-2025, 2018 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181173
18.
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.
Acta Haematol
; 143(1): 40-50, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31315113
19.
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
Cancer
; 125(11): 1830-1836, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30707764
20.
The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
Cancer
; 125(9): 1507-1517, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30694529